Memento Medicines, a privately held biotech developing biologic therapies for retinal disease, has launched with a $93 ...
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could ...
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm ...
Training a computer vision model on a 50:50 blend of synthetic and real eye images produces more reliable segmentation of the ...
The US Food and Drug Administration has accepted for review the Biologics License Application (BLA) for ONS-5010 (LYTENAVA) ...
Learn why newer anti‑VEGF options extend treatment for wet AMD, DME and RVO, signaling a shift from VEGF-only to multitarget ...
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for ...
NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial ...
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions ...
Conventional SLT requires gonioscopy-lens visualization; DSLT fires 120 pulses (1.8 mJ, 50 Hz) transsclerally with eye tracking, completing most sessions without contact. At 2 months, mean IOP fell ...
In “Durability with Aflibercept 8 mg in Retinal Vascular Diseases,” our panel explores how clinical trial data for ...
FDA labeling covers active and chronic TED, addressing a major evidentiary gap left by prior IGF-1R inhibition programs that primarily enrolled active disease populations. Two pivotal phase 3 trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results